COVID-19: an unexpected indication for anti-rheumatic therapies?
- PMID: 32374874
- PMCID: PMC7239095
- DOI: 10.1093/rheumatology/keaa194
COVID-19: an unexpected indication for anti-rheumatic therapies?
Figures

Comment in
-
Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease.Rheumatology (Oxford). 2020 Jul 1;59(7):1769-1770. doi: 10.1093/rheumatology/keaa217. Rheumatology (Oxford). 2020. PMID: 32472681 Free PMC article. No abstract available.
Similar articles
-
What is the role of rheumatologists in the era of COVID-19?Autoimmun Rev. 2020 Jun;19(6):102539. doi: 10.1016/j.autrev.2020.102539. Epub 2020 Apr 3. Autoimmun Rev. 2020. PMID: 32251716 Free PMC article. No abstract available.
-
Thoughts on COVID-19 and autoimmune diseases.Lupus Sci Med. 2020 Apr 3;7(1):e000396. doi: 10.1136/lupus-2020-000396. eCollection 2020. Lupus Sci Med. 2020. PMID: 32341791 Free PMC article.
-
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.Infection. 2020 Oct;48(5):767-771. doi: 10.1007/s15010-020-01476-7. Epub 2020 Jul 8. Infection. 2020. PMID: 32642806 Free PMC article.
-
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.Virus Res. 2020 Sep;286:198070. doi: 10.1016/j.virusres.2020.198070. Epub 2020 Jun 20. Virus Res. 2020. PMID: 32569708 Free PMC article. Review.
-
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.J Autoimmun. 2020 May;109:102442. doi: 10.1016/j.jaut.2020.102442. Epub 2020 Apr 2. J Autoimmun. 2020. PMID: 32253068 Free PMC article. Review.
Cited by
-
Médicaments rhumatologiques pour le traitement de l’infection par le COVID-19.Rev Rhum Ed Fr. 2020 May;87(3):150-152. doi: 10.1016/j.rhum.2020.03.010. Epub 2020 Apr 24. Rev Rhum Ed Fr. 2020. PMID: 32355446 Free PMC article. French. No abstract available.
-
Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease.Rheumatology (Oxford). 2020 Jul 1;59(7):1769-1770. doi: 10.1093/rheumatology/keaa217. Rheumatology (Oxford). 2020. PMID: 32472681 Free PMC article. No abstract available.
-
Old and new antirheumatic drugs for the treatment of COVID-19.Joint Bone Spine. 2020 May;87(3):195-197. doi: 10.1016/j.jbspin.2020.03.013. Joint Bone Spine. 2020. PMID: 32321635 Free PMC article. No abstract available.
-
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.Rheumatology (Oxford). 2021 Jan 5;60(1):399-407. doi: 10.1093/rheumatology/keaa587. Rheumatology (Oxford). 2021. PMID: 33020836 Free PMC article.
-
SARS-CoV-2-induced venous thromboembolism in a patient with VEXAS syndrome.Rheumatol Adv Pract. 2023 Jan 20;7(1):rkad012. doi: 10.1093/rap/rkad012. eCollection 2023. Rheumatol Adv Pract. 2023. PMID: 36742373 Free PMC article. No abstract available.
References
-
- Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. bioRxiv 2020, doi: 10.1101/2020.02.07.937862.
-
- World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 69. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2...(29 March 2020, date last accessed).
-
- Wu Z, McGoogan JM.. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020. (in press), doi: 10.1001/jama.2020.2648. - PubMed
-
- Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L. et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv 2020, doi: 10.1101/2020.02.10.20021832.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources